Capital Analysts LLC’s AbbVie ABBV Stock Holding History

Capital Analysts LLC’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Buy	7,055 +194	+3%	+$41.7K	0.04%	283
2026 Q1	$1.49M	Sell	6,861 -352	-5%	-$78.1K	0.04%	279
2025 Q4	$1.65M	Sell	7,213 -7	-0.1%	-$1.59K	0.05%	254
2025 Q3	$1.67M	Sell	7,220 -684	-9%	-$139K	0.05%	244
2025 Q2	$1.47M	Buy	7,904 +20	+0.3%	+$3.72K	0.05%	240
2025 Q1	$1.65M	Buy	7,884 +586	+8%	+$114K	0.06%	211
2024 Q4	$1.3M	Buy	7,298 +3	+0%	+$552	0.05%	220
2024 Q3	$1.44M	Buy	7,295 +1,458	+25%	+$272K	0.06%	210
2024 Q2	$1M	Buy	5,837 +330	+6%	+$54.7K	0.04%	244
2024 Q1	$1M	Buy	5,507 +593	+12%	+$102K	0.05%	242
2023 Q4	$761K	Sell	4,914 -362	-7%	-$52.8K	0.04%	263
2023 Q3	$787K	Buy	5,276 +437	+9%	+$64.2K	0.04%	248
2023 Q2	$652K	Sell	4,839 -108	-2%	-$15.8K	0.04%	272
2023 Q1	$788K	Buy	4,947 +295	+6%	+$45.1K	0.05%	243
2022 Q4	$751K	Buy	4,652 +217	+5%	+$33.3K	0.05%	253
2022 Q3	$595K	Sell	4,435 -118	-3%	-$16.9K	0.04%	251
2022 Q2	$697K	Buy	4,553 +374	+9%	+$57.1K	0.05%	236
2022 Q1	$677K	Sell	4,179 -167	-4%	-$24.3K	0.04%	243
2021 Q4	$588K	Sell	4,346 -1,529	-26%	-$181K	0.04%	248
2021 Q3	$634K	Buy	5,875 +1,004	+21%	+$115K	0.04%	237
2021 Q2	$549K	Sell	4,871 -1,702	-26%	-$192K	0.04%	244
2021 Q1	$711K	Buy	6,573 +2,206	+51%	+$236K	0.05%	227
2020 Q4	$468K	Buy	4,367 +68	+2%	+$6.54K	0.04%	195
2020 Q3	$377K	Buy	4,299 +17	+0.4%	+$1.6K	0.04%	217
2020 Q2	$420K	Buy	4,282 +171	+4%	+$15.1K	0.04%	189
2020 Q1	$313K	Buy	4,111 +15	+0.4%	+$1.28K	0.04%	179
2019 Q4	$363K	Buy	4,096 +227	+6%	+$18.8K	0.04%	200
2019 Q3	$292K	Sell	3,869 -969	-20%	-$66.4K	0.03%	202
2019 Q2	$352K	Buy	4,838 +1,356	+39%	+$107K	0.04%	192
2019 Q1	$280K	Sell	3,482 -11,282	-76%	-$923K	0.03%	193
2018 Q4	$1.36M	Buy	14,764 +851	+6%	+$74.8K	0.18%	97
2018 Q3	$1.32M	Buy	13,913 +364	+3%	+$34.5K	0.15%	123
2018 Q2	$1.25M	Buy	13,549 +174	+1%	+$17K	0.15%	112
2018 Q1	$1.27M	Buy	13,375 +1,016	+8%	+$112K	0.16%	102
2017 Q4	$1.2M	Sell	12,359 -4,485	-27%	-$423K	0.15%	114
2017 Q3	$1.5M	Buy	16,844 +783	+5%	+$59.6K	0.2%	84
2017 Q2	$1.16M	Buy	16,061 +302	+2%	+$20.3K	0.17%	97
2017 Q1	$1.03M	Buy	15,759 +1,732	+12%	+$109K	0.16%	94
2016 Q4	$878K	Buy	14,027 +480	+4%	+$29.3K	0.15%	103
2016 Q3	$854K	Buy	13,547 +1,479	+12%	+$95.7K	0.16%	104
2016 Q2	$747K	Buy	12,068 +403	+3%	+$24.6K	0.15%	107
2016 Q1	$666K	Sell	11,665 -2,089	-15%	-$116K	0.13%	122
2015 Q4	$815K	Sell	13,754 -14,392	-51%	-$829K	0.17%	115
2015 Q3	$1.53M	Buy	28,146 +12,490	+80%	+$813K	0.29%	88
2015 Q2	$1.05M	Sell	15,656 -2,141	-12%	-$140K	0.22%	98
2015 Q1	$1.04M	Buy	17,797 +357	+2%	+$21.6K	0.22%	94
2014 Q4	$1.14M	Buy	17,440 +683	+4%	+$43.1K	0.25%	84
2014 Q3	$968K	Buy	16,757 +206	+1%	+$11.4K	0.23%	91
2014 Q2	$934K	Buy	16,551 +147	+0.9%	+$7.71K	0.23%	94
2014 Q1	$843K	Sell	16,404 -1,666	-9%	-$84.2K	0.22%	97
2013 Q4	$954K	Sell	18,070 -1,023	-5%	-$50.3K	0.26%	90
2013 Q3	$854K	Buy	+19,093	New	+$846K	0.26%	98

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Analysts LLC's ABBV Position: Q2 2026 in Review

Capital Analysts LLC increased its AbbVie (ABBV) stake by 2.8% in Q2 2026, buying an estimated $41.7K and bringing the position to 7,055 shares worth $1.78M. The position accounts for 0.04% of the portfolio, ranked #283.

Capital Analysts LLC first reported a position in ABBV in Q3 2013 and has held it in 52 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Capital Analysts LLC held 7,055 shares of AbbVie worth $1.78M as of Q2 2026.
Capital Analysts LLC bought 194 AbbVie shares in Q2 2026, an estimated $41.7K.
AbbVie made up 0.04% of Capital Analysts LLC's portfolio in Q2 2026, its #283 holding.
Capital Analysts LLC first reported a position in AbbVie in Q3 2013 and has held it in 52 quarters since.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.